GlassScriptPhysician profile
Tomas Sevilla
NPI 1922189125
$9,121.44
in general payments reported to CMS, 2019-2025
32 companies · $858 in 2025
The $858 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,325 · 2020: $1,218 · 2021: $1,147 · 2022: $1,132 · 2023: $968 · 2024: $1,474 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,125 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,125.35 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,744.53 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $1,308.46 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $1,200.76 | 2019-2025 | Linzess, Viberzi, Creon |
| Lilly USA, LLC | $716.37 | 2019-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $694.24 | 2019-2022 | |
| Amgen INC. | $488.77 | 2019-2025 | Prolia, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $435.76 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $425.32 | 2019-2024 | Verquvo |
| Phathom Pharmaceuticals, INC. | $348.15 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $253.01 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $211.36 | 2022-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.37 | 2021-2024 | Jardiance |
| Eisai INC. | $172.74 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.19 | 2020-2024 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $124.98 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $103.15 | 2021-2022 | |
| Exact Sciences Corporation | $86.93 | 2023-2024 | Cologuard Collection Kit |
| Actelion Pharmaceuticals US, INC. | $72.00 | 2022 | |
| Glaxosmithkline, LLC. | $62.06 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Ironwood Pharmaceuticals, INC | $61.84 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $47.55 | 2024 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $42.21 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.55 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $24.21 | 2019 | |
| Astellas Pharma US INC | $21.32 | 2019 | |
| Abbott Laboratories | $20.13 | 2025 | Id Now Instrument |
| Mannkind Corporation | $20.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.71 | 2019 | |
| Optos, INC. | $17.09 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.65 | 2025 | Rexulti |
| Redhill Biopharma INC. | $13.06 | 2020 | |
| Allergan, INC. | $10.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tomas Sevilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.